Introduction: This study aimed to evaluate the prognostic significance of programmed cell death (PD)-1/PD-ligand 1 (PD-L1), PD-ligand 2 (PD-L2), and fibroblast growth factor receptor 3 (FGFR3) expression in bladder cancer (BC). Methods: A retrospective study was conducted on BC patients who underwent transurethral resection between 2005 and 2014. Of the initial 136 patients, 31 were excluded for not meeting the inclusion criteria, leaving 105 cases for the final analysis. The mRNA levels of PD-1/PD-L1/PD-L2 and FGFR3 were assessed using quantitative reverse transcription PCR and NanoString technology. Results: High expression of PD-1 and its ligands (PD-L1/PD-L2) showed a strong correlation with each other and was associated with poor clinical outcomes, including higher tumor stage, grade, and cancer-specific mortality (p < 0.001). Conversely, high FGFR3 expression was associated with improved survival and more favorable clinicopathological features. Interestingly, an inverse relationship was observed between FGFR3 and PD-1 (p = 0.032) and PD-L1 (p = 0.016) expression. High mRNA expression profiles of PD-1, PD-L1, PD-L2, and low FGFR3 expression were associated with worse cancer-specific survival (p < 0.001). Multivariate analysis revealed that advanced stage, low FGFR3 expression, and high PD-L2 expression are independent predictors of poor prognosis in BC patients. Conclusion: Our findings suggest that elevated levels of PD-1, PD-L1, and PD-L2, combined with reduced FGFR3 expression, may assist in identifying patients with poor outcomes and highlight their potential as prognostic biomarkers in BC.

1.
Siegel
RL
,
Giaquinto
AN
,
Jemal
A
.
Cancer statistics, 2024
.
CA Cancer J Clin
.
2024
;
74
(
1
):
12
49
.
2.
Netto
GJ
,
Amin
MB
,
Berney
DM
,
Compérat
EM
,
Gill
AJ
,
Hartmann
A
, et al
.
The 2022 world Health organization classification of tumors of the urinary system and male genital organs-Part B: prostate and urinary tract tumors
.
Eur Urol
.
2022
;
82
(
5
):
469
82
.
3.
Lopez-Beltran
A
,
Cookson
MS
,
Guercio
BJ
,
Cheng
L
.
Advances in diagnosis and treatment of bladder cancer
.
BMJ
.
2024
;
384
:
e076743
.
4.
Sjödahl
G
,
Eriksson
P
,
Patschan
O
,
Marzouka
NAD
,
Jakobsson
L
,
Bernardo
C
, et al
.
Molecular changes during progression from nonmuscle invasive to advanced urothelial carcinoma
.
Int J Cancer
.
2020
;
146
(
9
):
2636
47
.
5.
Thomas
J
,
Sun
M
,
Getz
T
,
Ho
B
,
Nauseef
JT
,
Tagawa
ST
.
Antibody-drug conjugates for urothelial carcinoma
.
Urol Oncol
.
2023
;
41
(
10
):
420
8
.
6.
Peng
M
,
Chu
X
,
Peng
Y
,
Li
D
,
Zhang
Z
,
Wang
W
, et al
,
Targeted therapies in bladder cancer: signaling pathways, applications, and challenges
.
MedComm
.
2023
;
4
(
6
):
e455
.
7.
Han
Y
,
Liu
D
,
Li
L
.
PD-1/PD-L1 pathway: current researches in cancer
.
Am J Cancer Res
.
2020
;
10
(
3
):
727
42
.
8.
Tamalunas
A
,
Aydogdu
C
,
Unterrainer
LM
,
Schott
M
,
Rodler
S
,
Ledderose
S
, et al
.
The vanishing clinical value of PD-L1 status as a predictive biomarker in the first-line treatment of urothelial carcinoma of the bladder
.
Cancers
.
2024
;
16
(
8
):
1536
.
9.
Sanguedolce
F
,
Falagario
UG
,
Zanelli
M
,
Palicelli
A
,
Zizzo
M
,
Busetto
GM
, et al
.
Integrating the PD-L1 prognostic biomarker in non-muscle invasive bladder cancer in clinical practice-A comprehensive review on state-of-the-art advances and critical issues
.
J Clin Med
.
2024
;
13
(
8
):
2182
.
10.
Sharpe
AH
,
Pauken
KE
.
The diverse functions of the PD1 inhibitory pathway
.
Nat Rev Immunol
.
2018
;
18
(
3
):
153
67
.
11.
Bilé-Silva
A
,
Lopez-Beltran
A
,
Blanca
A
,
Lopez-Rios
F
,
Gómez-Gómez
E
,
Cimadamore
A
, et al
.
Clinical utility of checkpoint inhibitors against metastatic bladder cancer: overcoming challenges to find a way forward
.
Expert Opin Biol Ther
.
2023
;
23
(
5
):
407
18
.
12.
Ariafar
A
,
Ghaedi
M
,
Rezaeifard
S
,
Shahriari
S
,
Zeighami
S
,
Ghaderi
A
, et al
.
Clinical relevance and prognostic significance of PD-1/PD-Ls in non-metastatic bladder cancer: a role for PD-L2
.
Mol Immunol
.
2020
;
124
:
35
41
.
13.
Lopez-Beltran
A
,
Blanca
A
,
Cimadamore
A
,
Gogna
R
,
Montironi
R
,
Cheng
L
.
Molecular classification of bladder urothelial carcinoma using NanoString-based gene expression analysis
.
Cancers
.
2021
;
13
(
21
):
5500
.
14.
Bellmunt
J
,
Powles
T
,
Vogelzang
NJ
.
A review on the evolution of PD-1/PD-L1 immunotherapy for bladder cancer: the future is now
.
Cancer Treat Rev
.
2017
;
54
:
58
67
.
15.
Zhu
L
,
Sun
J
,
Wang
L
,
Li
Z
,
Wang
L
,
Li
Z
.
Prognostic and clinicopathological significance of PD-L1 in patients with bladder cancer: a meta-analysis
.
Front Pharmacol
.
2019
;
10
:
962
.
16.
Knowles
MA
.
FGFR3: a central player in bladder cancer pathogenesis
.
Bladder Cancer
.
2020
;
6
(
4
):
403
23
.
17.
Kang
HW
,
Kim
YH
,
Jeong
P
,
Park
C
,
Kim
WT
,
Ryu
DH
, et al
.
Expression levels of FGFR3 as a prognostic marker for the progression of primary pT1 bladder cancer and its association with mutation status
.
Oncol Lett
.
2017
;
14
(
3
):
3817
24
.
18.
Kardoust Parizi
M
,
Margulis
V
,
Lotan
Y
,
Mori
K
,
Shariat
SF
.
Fibroblast growth factor receptor: a systematic review and meta-analysis of prognostic value and therapeutic options in patients with urothelial bladder carcinoma
.
Urol Oncol
.
2021
;
39
(
7
):
409
21
.
19.
Rose
TL
,
Weir
WH
,
Mayhew
GM
,
Shibata
Y
,
Eulitt
P
,
Uronis
JM
, et al
.
Fibroblast growth factor receptor 3 alterations and response to immune checkpoint inhibition in metastatic urothelial cancer: a real world experience
.
Br J Cancer
.
2021
;
125
(
9
):
1251
60
.
20.
Kawahara
T
,
Ishiguro
Y
,
Ohtake
S
,
Kato
I
,
Ito
Y
,
Ito
H
, et al
.
PD-1 and PD-L1 are more highly expressed in high-grade bladder cancer than in low-grade cases: PD-L1 might function as a mediator of stage progression in bladder cancer
.
BMC Urol
.
2018
;
18
(
1
):
97
.
21.
Wang
L
,
Gong
Y
,
Saci
A
,
Szabo
PM
,
Martini
A
,
Necchi
A
, et al
.
Fibroblast growth factor receptor 3 alterations and response to PD-1/PD-L1 blockade in patients with metastatic urothelial cancer
.
Eur Urol
.
2019
;
76
(
5
):
599
603
.
22.
Blinova
E
,
Buzdin
A
,
Enikeev
D
,
Roshchin
D
,
Suntsova
M
,
Samyshina
E
, et al
.
Prognostic role of FGFR3 expression status and tumor-related MicroRNAs level in association with PD-L1 expression in primary luminal non-muscular invasive bladder carcinoma
.
Life
.
2020
;
10
(
11
):
305
.
23.
Brierley
J
,
Gospodarowicz
MK
,
Wittekind
C
,
TNM classification of malignant tumours
. 8th ed. Chichester, West Sussex, UK;
Hoboken, NJ
:
John Wiley & Sons, Inc
.
2017
.
24.
Blanca
A
,
Lopez-Beltran
A
,
Lopez-Porcheron
K
,
Gomez-Gomez
E
,
Cimadamore
A
,
Bilé-Silva
A
, et al
.
Risk classification of bladder cancer by gene expression and molecular subtype
.
Cancers
.
2023
;
15
(
7
):
2149
.
25.
Guercio
BJ
,
Iyer
G
,
Rosenberg
JE
.
Developing precision medicine for bladder cancer
.
Hematol Oncol Clin North Am
.
2021
;
35
(
3
):
633
53
.
26.
Bardoli
AD
,
Afshar
M
,
Viney
R
,
Foster
M
,
Porfiri
E
,
Zarkar
A
, et al
.
The PD-1/PD-L1 axis in the pathogenesis of urothelial bladder cancer and evaluating its potential as a therapeutic target
.
Future Oncol
.
2016
;
12
(
5
):
595
600
.
27.
di Martino
E
,
Tomlinson
DC
,
Williams
SV
,
Knowles
MA
.
A place for precision medicine in bladder cancer: targeting the FGFRs
.
Future Oncol
.
2016
;
12
(
19
):
2243
63
.
28.
Dowell
AC
,
Munford
H
,
Goel
A
,
Gordon
NS
,
James
ND
,
Cheng
KK
, et al
.
PD-L2 is constitutively expressed in normal and malignant urothelium
.
Front Oncol
.
2021
;
11
:
626748
.
29.
Wang
B
,
Pan
W
,
Yang
M
,
Yang
W
,
He
W
,
Chen
X
, et al
.
Programmed death ligand-1 is associated with tumor infiltrating lymphocytes and poorer survival in urothelial cell carcinoma of the bladder
.
Cancer Sci
.
2019
;
110
(
2
):
489
98
.
30.
Blinova
E
,
Enikeev
D
,
Roshchin
D
,
Samyshina
E
,
Deryabina
O
,
Tertychnyy
A
, et al
.
Relapse-free survival and PD-L1 expression in first high- and low-grade relapsed luminal, basal and double-negative P53-mutant non-muscular invasive bladder cancer depending on previous chemo- and immunotherapy
.
Cancers
.
2020
;
12
(
5
):
1316
.
31.
Kumar
U
,
Anthony
ML
,
Sahai
R
,
Mittal
A
,
Durgapal
P
,
Kishore
S
.
Immunoexpression of PD-L1 and PD-1 and its clinicopathological correlation in urothelial carcinomas
.
J Lab Physicians
.
2022
;
14
(
2
):
197
201
.
32.
Lopez-Beltran
A
,
Blanca
A
,
Cimadamore
A
,
Gogna
R
,
Montironi
R
,
Cheng
L
.
Molecular classification of bladder urothelial carcinoma using NanoString-based gene expression analysis
.
Cancers (Basel)
.
2021
;
13
(
21
):
5500
.
33.
Solinas
C
,
Aiello
M
,
Rozali
E
,
Lambertini
M
,
Willard-Gallo
K
,
Migliori
E
.
Programmed cell death-ligand 2: a neglected but important target in the immune response to cancer
.
Transl Oncol
.
2020
;
13
(
10
):
100811
.
34.
Takamori
S
,
Takada
K
,
Azuma
K
,
Jogo
T
,
Shimokawa
M
,
Toyokawa
G
, et al
.
Prognostic impact of programmed death-ligand 2 expression in primary lung adenocarcinoma patients
.
Ann Surg Oncol
.
2019
;
26
(
6
):
1916
24
.
35.
Yang
Y
,
Wang
X
,
Bai
Y
,
Feng
D
,
Li
A
,
Tang
Y
, et al
.
Programmed death-ligand 2 (PD-L2) expression in bladder cancer
.
Urol Oncol
.
2020
;
38
(
6
):
603.e9
15
.
36.
Hendri
AZ
,
Soerohardjo
I
,
Heriyanto
DS
,
Khalilullah
SA
,
Dany
YA
,
Danurdoro
A
.
Prognostic significance of PD-L2 expression in association with neutrophil-to-lymphocyte ratio in urothelial carcinoma of the bladder
.
Asian Pac J Cancer Prev
.
2023
;
24
(
8
):
2673
9
.
37.
van Rhijn
BWG
,
Mertens
LS
,
Mayr
R
,
Bostrom
PJ
,
Real
FX
,
Zwarthoff
EC
, et al
.
FGFR3 mutation status and FGFR3 expression in a large bladder cancer cohort treated by radical cystectomy: implications for anti-FGFR3 treatment
.
Eur Urol
.
2020
;
78
(
5
):
682
7
.
38.
Mahe
M
,
Dufour
F
,
Neyret-Kahn
H
,
Moreno-Vega
A
,
Beraud
C
,
Shi
M
, et al
.
An FGFR3/MYC positive feedback loop provides new opportunities for targeted therapies in bladder cancers
.
EMBO Mol Med
.
2018
;
10
(
4
):
e8163
.
39.
Kacew
A
,
Sweis
RF
.
FGFR3 alterations in the era of immunotherapy for urothelial bladder cancer
.
Front Immunol
.
2020
;
11
:
575258
.
40.
Thibault
C
,
Loriot
Y
.
Emerging targeted therapy for bladder cancer
.
Hematol Oncol Clin North Am
.
2021
;
35
(
3
):
585
96
.
41.
Jing
W
,
Wang
G
,
Cui
Z
,
Xiong
G
,
Jiang
X
,
Li
Y
, et al
.
FGFR3 destabilizes PD-L1 via NEDD4 to control T cell-mediated bladder cancer immune surveillance
.
Cancer Res
.
2022
;
82
(
1
):
114
129
.
You do not currently have access to this content.